Investor Presentation • Oct 4, 2021
Investor Presentation
Open in ViewerOpens in native device viewer
Press Release
Paris, France, October 4, 2021, 7:30 am CEST – GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced that oral presentations on LUMEVOQ® and GS030 will be featured at the 2021 ASRS and ESGCT meetings in October. Senior management will also attend and present at several investor and industry conferences in the same month.
October 4-5, 2021 – Virtual
Bernard Gilly, Co-founder & Chief Executive Officer, will present on Monday October 4, 2021, at 8.00 am ET and the management team will host investor meetings during the conference.
A webcast of the fireside chat will be available athttps://bit.ly/3zZOGsM for 90 days.
October 4-5, 2021 – Virtual GenSight Biologics' management team will host investor meetings during the conference.
October 7, 2021 – San Antonio, Texas (United States) & Virtual Magali Taiel, MD, Chief Medical Officer, will present on Thursday October 7, 2021, at 9.09 am CDT.
"Optogenetics in the Clinic: Safety and Efficacy Updates on the Phase I/II Clinical Trial PIONEER" will be presented by Joseph Martel, MD, University of Pittsburgh School of Medicine, United States and Investigator in the PIONEER trial.
October 12-14, 2021 – Carlsbad, California (United States) & Virtual
Magali Taiel, MD, Chief Medical Officer, pre-recorded a Company presentation that will be available during the conference.
"The phase III REFLECT trial: Efficacy and safety of bilateral gene therapy for Leber Hereditary Optic Neuropathy (LHON)" will be presented by Patrick Yu Wai Man, MD, University of Cambridge, United Kingdom and Investigator in the REFLECT trial.
"Partial recovery of visual function in a blind patient after optogenetic therapy for non-syndromic Retinitis Pigmentosa" will be presented by José-Alain Sahel, MD, University of Pittsburgh School of Medicine, United States and Co-founder of GenSight Biologics.
GenSight Biologics' management team will also present at the following conferences:
Mitochondrial Diseases Conference 2021 by Mitocon // October 15-16, virtual Advancing Gene Therapy 2021 // October 18-20, Boston, USA & virtual
Chief Financial Officer Thomas Gidoin [email protected] +33 (0)1 76 21 72 20
Investor Relations Guillaume van Renterghem [email protected] +41 (0)76 735 01 31
Media Relations Jeanene Timberlake [email protected] +1-646-770-8858
Retail Investors James Palmer [email protected] +33 (0)7 60 92 77 74
GenSight Biologics S.A. is a clinical-stage biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders. GenSight Biologics' pipeline leverages two core technology platforms, the Mitochondrial Targeting Sequence (MTS) and optogenetics, to help preserve or restore vision in patients suffering from blinding retinal diseases. GenSight Biologics' lead product candidate, LUMEVOQ® (GS010; lenadogene nolparvovec), has been submitted for marketing approval in Europe for the treatment of Leber Hereditary Optic Neuropathy (LHON), a rare mitochondrial disease affecting primarily teens and young adults that leads to irreversible blindness. Using its gene therapy-based approach, GenSight Biologics' product candidates are designed to be administered in a single treatment to each eye by intravitreal injection to offer patients a sustainable functional visual recovery.
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.